ArticleCell reports. Medicine2020
Human T Cells Expressing a CD19 CAR-T Receptor Provide Insights into Mechanisms of Human CD19-Positive β Cell Destruction.
Article in Cell reports. Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Programmed cell death in metabolic syndrome: From molecular mechanisms to therapeutic strategies (Review).International journal of molecular medicine · 2026Review
- Plasma Gasdermin D as a Biomarker for Pyroptosis in Early Detection of Newly Diagnosed Type 2 Diabetes Mellitus.EJIFCC · 2026Article
- Immune modulation for β-cell replacement in type 1 diabetes.Frontiers in immunology · 2026Review
- Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases.Journal of hematology & oncology · 2025Review
- Systematic characterization of existing and novel inducible transgenic systems in human pluripotent stem cells after prolonged differentiation.bioRxiv : the preprint server for biology · 2025Article
- Immune Evasion in Stem Cell-Based Diabetes Therapy-Current Strategies and Their Application in Clinical Trials.Biomedicines · 2025Review
- Pyroptosis-Mediator GSDMD in Plasma: A Promising Biomarker for Early Diagnosis of Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs.Science (New York, N.Y.) · 2024Article
- Multiplex Genome Editing of Human Pluripotent Stem Cells Using Cpf1.Bio-protocol · 2024Article
- The role of regulated necrosis in diabetes and its complications.Journal of molecular medicine (Berlin, Germany) · 2024Review
- Autoimmune CD8+ T cells in type 1 diabetes: from single-cell RNA sequencing to T-cell receptor redirection.Frontiers in endocrinology · 2024Review
- The role of B cells in the pathogenesis of type 1 diabetes.Frontiers in immunology · 2024Review
- Chimeric antigen receptor T-cell therapy in autoimmune diseases.Frontiers in immunology · 2024Review
- Dysfunctions, molecular mechanisms, and therapeutic strategies of pancreatic β-cells in diabetes.Apoptosis : an international journal on programmed cell death · 2023Review
- Single-cell transcriptome analysis profiles the expression features of TMEM173 in BM cells of high-risk B-cell acute lymphoblastic leukemia.BMC cancer · 2023Article
- The nuclear receptor THRB facilitates differentiation of human PSCs into more mature hepatocytes.Cell stem cell · 2022Article
- Stem Cell-Derived Islets for Type 2 Diabetes.International journal of molecular sciences · 2022Review
- Prognosis and immune features of pyroptosis-related RNA patterns in low-grade glioma.Frontiers in oncology · 2022Article
- Advances in Pancreatic Islet Transplantation Sites for the Treatment of Diabetes.Frontiers in endocrinology · 2021Review
- Immune Protection of Stem Cell-Derived Islet Cell Therapy for Treating Diabetes.Frontiers in endocrinology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Autoimmune destruction of pancreatic β cells underlies type 1 diabetes (T1D). To understand T cell-mediated immune effects on human pancreatic β cells, we combine β cell-specific expression of a model antigen, CD19, and anti-CD19 chimeric antigen receptor T (CAR-T) cells. Coculturing CD19-expressing β-like cells and CD19 CAR-T cells results in T cell-mediated β-like cell death with release of activated T cell cytokines. Transcriptome analysis of β-like cells and human islets treated with conditioned medium of the immune reaction identifies upregulation of immune reaction genes and the pyroptosis mediator
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.